<SEC-DOCUMENT>0001615774-18-003436.txt : 20180508
<SEC-HEADER>0001615774-18-003436.hdr.sgml : 20180508
<ACCEPTANCE-DATETIME>20180508073207
ACCESSION NUMBER:		0001615774-18-003436
CONFORMED SUBMISSION TYPE:	6-K
PUBLIC DOCUMENT COUNT:		6
CONFORMED PERIOD OF REPORT:	20180508
FILED AS OF DATE:		20180508
DATE AS OF CHANGE:		20180508

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Immuron Ltd
		CENTRAL INDEX KEY:			0001660046
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			C3
		FISCAL YEAR END:			0630

	FILING VALUES:
		FORM TYPE:		6-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-38104
		FILM NUMBER:		18812958

	BUSINESS ADDRESS:	
		STREET 1:		62 LYGON STREET
		STREET 2:		LEVEL 3
		CITY:			CARLTON, VICTORIA
		STATE:			C3
		ZIP:			3053
		BUSINESS PHONE:		61 03 9824 5254

	MAIL ADDRESS:	
		STREET 1:		62 LYGON STREET
		STREET 2:		LEVEL 3
		CITY:			CARLTON, VICTORIA
		STATE:			C3
		ZIP:			3053
</SEC-HEADER>
<DOCUMENT>
<TYPE>6-K
<SEQUENCE>1
<FILENAME>s110051_6-k.htm
<DESCRIPTION>6-K
<TEXT>
<html><head>
<title></title></head>
<body style="font: 10pt Times New Roman, Times, Serif">
<p style="font: 14pt Times New Roman, Times, Serif; font-weight: normal; text-align: center;"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>UNITED
STATES</b></font><br>
<font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>SECURITIES AND EXCHANGE COMMISSION<br>
Washington, D.C.
20549</b></font></p>
<p style="font: 12pt Times New Roman, Times, Serif; font-weight: normal; text-align: center;"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Form
6-K</b></font></p>
<p style="font: 10pt Times New Roman, Times, Serif; font-weight: normal; text-align: center;"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>REPORT
OF FOREIGN PRIVATE ISSUER</b></font><br>
<font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>PURSUANT TO RULE 13a-16 OR 15d-16 UNDER<br>
THE SECURITIES
EXCHANGE ACT OF 1934</b></font></p>
<p style="font: 10pt Times New Roman, Times, Serif; font-weight: normal; text-align: center;"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
the Month of May&#160;2018</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; font-weight: normal; text-align: center;"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Commission
File Number: 001-38104</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; font-weight: normal; text-align: center;"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><u>IMMURON
LIMITED</u></b> </font><br>
<font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Name of Registrant)</font></p>

<p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif"><b><u>Level 3,&#160;62 Lygon Street,
Carlton South, Victoria,&#160;3053, Australia</u></b> </font><br>
<font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Address of principal executive office)</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; font-weight: normal; text-align: left;"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Indicate
by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; font-weight: normal; text-align: center;"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Form
20-F &#x2612; &nbsp;Form 40-F &#x2610;</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; font-weight: normal; text-align: left;"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Indicate
by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): &#x2610;</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; font-weight: normal; text-align: left;"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Indicate
by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): &#x2610;</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; font-weight: normal; text-align: left;"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Indicate
by check mark whether by furnishing the information contained in this Form, the registrant is also thereby furnishing the information
to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; font-weight: normal; text-align: left;"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Yes
&#x2610; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;No &#x2612;</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; font-weight: normal; text-align: left;"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
&#x0093;Yes&#x0094; is marked, indicate below the file number assigned to the registrant in connection with Rule 12g3-2(b):
82-</font></p>

<p style="font: normal 10pt Times New Roman, Times, Serif; text-align: left"></p>

<!-- Field: Page; Sequence: 1 -->
    <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt">&nbsp;</P></div>
    <div style="page-break-before: always; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></div>
    <!-- Field: /Page -->

<p style="font: normal 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</p>
<p style="font: 10pt Times New Roman, Times, Serif; font-weight: bold; text-align: center; text-transform: uppercase;"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>IMMURON
LIMITED</b></font></p>
<p style="font: 10pt Times New Roman, Times, Serif; font-weight: bold; text-align: center; text-transform: uppercase;"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><u>EXPLANATORY
NOTE</u></b></font></p>
<p style="font: 10pt Times New Roman, Times, Serif; font-weight: normal; text-align: justify;">Immuron Limited (the &ldquo;Company&rdquo;)
published an announcement (the &ldquo;Public Notice&rdquo;) to the Australian Securities Exchange on May 8, 2018 titled &ldquo;IMC
Preclinical Study Reports Reduction in Colitis Symptoms&rdquo;.</p>

<p style="font: normal 10pt Times New Roman, Times, Serif; text-align: justify">A copy of the Public Notice is attached as an
exhibit to this report on Form 6-K.</p>

<p style="font: normal 10pt Times New Roman, Times, Serif; text-align: justify">This report on Form 6-K (including the exhibit
hereto) shall not be deemed to be &ldquo;filed&rdquo; for purposes of the Securities Exchange Act of 1934, as amended (the &ldquo;Exchange
Act&rdquo;) and shall not be incorporated by reference into any filing under the Securities Act of 1933, as amended, except as
shall be expressly set forth by specific reference in such filing.&nbsp;</p>



<p style="font: 10pt Times New Roman, Times, Serif; font-weight: normal; text-align: justify"></p>
<p style="font: 10pt Times New Roman, Times, Serif; font-weight: bold; text-align: center; text-transform: uppercase;"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>EXHIBITS</b></font></p>
<table cellspacing="0" cellpadding="0" border="0" style="width: 100%; border-collapse: collapse; margin-top: 4px;">
<tr style="background-color: #FFFFFF;">
<td style="width: 8%;border-bottom: black 1pt solid;" valign="top"><p style="font: 10pt Times New Roman, Times, Serif; font-weight: normal; margin-left: 0px; text-align: left;"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Exhibit
</b>
<b>Number</b></font></p></td>
<td style="width: 1%;" valign="top"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></td>
<td style="width: 91%; border-bottom: black 1pt solid; text-align: left; vertical-align: bottom"><p style="font: 10pt Times New Roman, Times, Serif; font-weight: normal; margin-left: 0px"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
<b>Description</b></font></p></td></tr>
<tr style="background-color: #FFFFFF;">
<td style="width: 8%;" valign="top"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></td>
<td style="width: 1%;" valign="top"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></td>
<td style="width: 91%;" valign="top"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></td></tr>
<tr style="background-color: #FFFFFF;">
<td style="width: 8%;" valign="top"><p style="font: 10pt Times New Roman, Times, Serif; font-weight: normal; margin-left: 0px; text-align: center;"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="s110051_ex99-1.htm">99.1</a></font></p></td>
<td style="width: 1%;" valign="top"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></td>
<td style="width: 91%;" valign="top"><p style="font: 10pt Times New Roman, Times, Serif; font-weight: normal; margin-left: 0px; text-align: left;"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="s110051_ex99-1.htm">IMC Preclinical Study Reports Reduction in Colitis Symptoms</a></font></p></td></tr></table>


<p style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; text-transform: uppercase">&nbsp;</p>

<!-- Field: Page; Sequence: 2 -->
    <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt">&nbsp;</P></div>
    <div style="page-break-before: always; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></div>
    <!-- Field: /Page -->

<p style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; text-transform: uppercase">&nbsp;</p>

<p style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; text-transform: uppercase"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>SIGNATURE</b></font></p>
<p style="font: 10pt Times New Roman, Times, Serif; font-weight: normal; text-indent: 44px; text-align: justify;"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf
by the undersigned, thereunto duly authorized.</font></p>
<table cellspacing="0" cellpadding="0" border="0" style="width: 100%; border-collapse: collapse; margin-top: 4px">
<tr style="background-color: #FFFFFF;">
<td style="vertical-align: top"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></td>
<td colspan="2" style="vertical-align: top"><p style="font: 10pt Times New Roman, Times, Serif; font-weight: normal; margin-left: 0px; text-align: left;"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>IMMURON
LIMITED</b></font></p></td></tr>
<tr style="background-color: #FFFFFF;">
<td style="vertical-align: top"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></td>
<td colspan="2" style="vertical-align: top"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></td></tr>
<tr style="background-color: #FFFFFF;">
<td style="vertical-align: top"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></td>
<td colspan="2" style="vertical-align: top"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><img src="img004_v1.jpg" alt="-s- peter vaughan">&#160;</font></td></tr>
<tr style="background-color: #FFFFFF;">
<td style="vertical-align: top"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></td>
<td colspan="2" style="vertical-align: top"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></td></tr>
<tr style="background-color: #FFFFFF;">
<td style="vertical-align: top; width: 49%"><p style="font: 10pt Times New Roman, Times, Serif; font-weight: normal; margin-left: 0px; text-align: left;"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date:
May 8,&#160;2018</font></p></td>
<td style="vertical-align: top; width: 3%"><p style="font: 10pt Times New Roman, Times, Serif; font-weight: normal; margin-left: 0px; text-align: left;"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</font></p></td>
<td style="border-bottom: black 1pt solid; vertical-align: top; width: 47%"><p style="font: 10pt Times New Roman, Times, Serif; font-weight: normal; margin-left: 0px; text-align: left;"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/
Peter Vaughan</font></p></td></tr>
<tr style="background-color: #FFFFFF;">
<td style="vertical-align: top"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></td>
<td style="vertical-align: top"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></td>
<td style="vertical-align: top"><p style="font: 10pt Times New Roman, Times, Serif; font-weight: normal; margin-left: 0px; text-align: left;"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Peter
Vaughan</font></p></td></tr>
<tr style="background-color: #FFFFFF;">
<td style="vertical-align: top"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></td>
<td style="vertical-align: top"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></td>
<td style="vertical-align: top"><p style="font: 10pt Times New Roman, Times, Serif; font-weight: normal; margin-left: 0px; text-align: left;"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Joint
Chief Financial Officer</font></p></td></tr></table>
<p style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; text-transform: uppercase">&nbsp;</p>
<!-- Field: Page; Sequence: 3; Options: Last -->
    <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt">&nbsp;</P></div>
    <!-- Field: /Page -->

</body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>s110051_ex99-1.htm
<DESCRIPTION>EXHIBIT 99.1
<TEXT>
<html><head>
<title></title></head>
<body style="font: 10pt Times New Roman, Times, Serif">
<p style="font: 10pt Times New Roman, Times, Serif; font-weight: normal; text-align: right"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Exhibit
99.1</b></font></p>

<p style="font: 10pt Times New Roman, Times, Serif; font-weight: bold; text-align: center;"><img src="img001_v1.jpg" alt="(IMMURON LIMITED LOGO)"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</font></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 28.35pt; text-align: center"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 28.35pt; text-align: center"><b>Immuron Reports Significant Alleviation
of Colitis Symptoms in Preclinical Program</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 28.35pt; text-align: center"><b>&nbsp;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 28.35pt; text-align: center"><b>Results confirm LPS Antagonist
action of IMM-124E offers a novel therapeutic approach to induce or maintain remission in IBD</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 28.35pt"><b>&nbsp;</b></p>

<p style="font: 10pt/130% Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Melbourne, Australia, May 8, 2018:</b>
Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian microbiome biopharmaceutical company focused on developing and commercializing
orally delivered targeted polyclonal antibodies for the treatment of inflammatory mediated and infectious diseases, is today pleased
to announce the successful completion of its colitis preclinical program at the University of Z&uuml;rich, Switzerland.</p>

<p style="font: 10pt/130% Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt/130% Times New Roman, Times, Serif; margin: 0; text-align: justify">Immuron is pleased to report that oral
administration of IMM-124E was successfully able to treat mice with immunologically induced colitis. The University of Z&uuml;rich
research revealed that IMM-124E offered a significant therapeutic benefit on clinically meaningful study parameters.</p>

<p style="font: 10pt/130% Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt/130% Times New Roman, Times, Serif; margin: 0; text-align: justify">In contrast to the results reported in
April 2017 using an acute colitis model the latest results were generated in the T cell transfer model which utilizes immunodeficient
mice which are deficient in functional B and T lymphocytes. In this model chronic colitis is induced immunologically not chemically.
IMM-124E was administered orally after the onset of colitis symptoms such as weight loss and macroscopically inflamed colon were
confirmed by colonoscopy prior to the initiation of treatment.</p>

<p style="font: 10pt/130% Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt/130% Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="color: black">The results
reported clearly demonstrated that oral </font>treatment with IMM-124E resulted in significant alleviation of colitis symptoms,
including;</p>

<p style="font: 10pt/130% Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</p>

<table cellpadding="0" cellspacing="0" width="100%" style="font: 10pt/130% Arial, Helvetica, Sans-Serif; margin-top: 0; margin-bottom: 0"><tr style="vertical-align: top">
<td style="width: 20.4pt"></td><td style="width: 18pt"><font style="font-family: Symbol">&#183;</font></td><td style="text-align: justify"><font style="font-family: Times New Roman, Times, Serif"><b>Reduced weight loss</b></font></td></tr></table>

<table cellpadding="0" cellspacing="0" width="100%" style="font: 10pt/130% Arial, Helvetica, Sans-Serif; margin-top: 0; margin-bottom: 0"><tr style="vertical-align: top">
<td style="width: 20.4pt"></td><td style="width: 18pt"><font style="font-family: Symbol">&#183;</font></td><td style="text-align: justify"><font style="font-family: Times New Roman, Times, Serif"><b>Reduced disease activity scores</b></font></td></tr></table>

<table cellpadding="0" cellspacing="0" width="100%" style="font: 10pt/130% Arial, Helvetica, Sans-Serif; margin-top: 0; margin-bottom: 0"><tr style="vertical-align: top">
<td style="width: 20.4pt"></td><td style="width: 18pt"><font style="font-family: Symbol">&#183;</font></td><td style="text-align: justify"><font style="font-family: Times New Roman, Times, Serif"><b>Reduced shortening of the colon</b></font></td></tr></table>

<table cellpadding="0" cellspacing="0" width="100%" style="font: 10pt/130% Arial, Helvetica, Sans-Serif; margin-top: 0; margin-bottom: 0"><tr style="vertical-align: top">
<td style="width: 20.4pt"></td><td style="width: 18pt"><font style="font-family: Symbol">&#183;</font></td><td style="text-align: justify"><font style="font-family: Times New Roman, Times, Serif"><b>Reduced levels of macroscopically detectable
colitis</b></font></td></tr></table>

<table cellpadding="0" cellspacing="0" width="100%" style="font: 10pt/130% Arial, Helvetica, Sans-Serif; margin-top: 0; margin-bottom: 0"><tr style="vertical-align: top">
<td style="width: 20.4pt"></td><td style="width: 18pt"><font style="font-family: Symbol">&#183;</font></td><td style="text-align: justify"><font style="font-family: Times New Roman, Times, Serif"><b>Histology of the terminal and proximal
colon also confirmed reduced colitis in the drug treatment arms.</b></font></td></tr></table>

<p style="font: 10pt/130% Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt/130% Times New Roman, Times, Serif; margin: 0; text-align: justify">The research work has been submitted for
presentation at the annual United European Gastroenterology Week conference which will be held on the 20<sup>th</sup> to 24<sup>th</sup>
of October 2018 in Vienna, Austria.</p>

<p style="font: 10pt/130% Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt/130% Times New Roman, Times, Serif; margin: 0; text-align: justify"><i>&quot;<b>This study concludes our comprehensive
preclinical program to evaluate the therapeutic potential of IMM-124E in our established colitis animal models,</b>&quot; </i>said
Gerhard Rogler, Professor of Gastroenterology and Hepatology from the University of Z&uuml;rich, Switzerland and the study lead
Principal Investigator.</p>

<p style="font: 10pt/130% Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt/130% Times New Roman, Times, Serif; margin: 0 13.8pt 0 0; text-align: justify"><font style="color: black"><i>&quot;</i></font><i>Our
results clearly demonstrate that treatment with IMM-124E significantly reduces intestinal inflammation via reducing the accumulation
and differentiation of pathogenic T cells, while concomitantly enhancing the induction of regulatory cells. This indicates that
IMM-124E inhibits <font style="color: black">lipopolysaccharide</font> (LPS)-mediated effects on the mucosal immune system, resulting
in reduced intestinal inflammation. Summarized, our findings indicate that IMM-124E administration represents a novel therapeutic
strategy to induce or maintain remission in IBD patients</i>&rdquo;.</p>



<p style="font: bold 10pt Times New Roman, Times, Serif; text-align: left"></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; text-align: left"></p>

<p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center"><img src="img002_v1.jpg" alt="(LOGO)">&nbsp;</p>
<!-- Field: Page; Sequence: 1 -->
    <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt">&nbsp;</P></div>
    <div style="page-break-before: always; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></div>
    <!-- Field: /Page -->
<p style="font: 10pt Times New Roman, Times, Serif; font-weight: normal; text-align: justify;"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
<p style="font: normal 10pt Times New Roman, Times, Serif; font-weight: normal; text-align: right; border-bottom: Black 1pt solid"><img src="img003_v1.jpg" alt="(IMMURON LIMITED LOGO)">&nbsp;</p>

<p style="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"></p>

<p style="font: 10pt/130% Times New Roman, Times, Serif; margin: 0 9.55pt 0 0; text-align: justify">Immuron Interim CEO Dr. Jerry
Kanellos commented:</p>

<p style="font: 10pt/130% Times New Roman, Times, Serif; margin: 0 9.55pt 0 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt/130% Times New Roman, Times, Serif; margin: 0 16.65pt 0 14.2pt; text-align: justify"><font style="color: black"><i>&ldquo;The
IMM-124E drug candidate has been developed to target the endotoxin, LPS in the gut and prevent it translocating into the portal
circulation. This first in class mechanism of action was recently confirmed in our </i></font><i><b>Non-Alcoholic Steatohepatitis</b>
<font style="color: black">(NASH) clinical study, where IMM-124E demonstrated a statistically significant reduction in serum LPS
levels, when compared to placebo in patients with biopsy confirmed NASH.</font></i></p>

<p style="font: 10pt/130% Times New Roman, Times, Serif; margin: 0 16.65pt 0 14.2pt; text-align: justify"><i>&nbsp;</i></p>

<p style="font: 10pt/130% Times New Roman, Times, Serif; margin: 0 16.65pt 0 14.2pt; text-align: justify"><font style="color: black"><i>The
University of Z&uuml;rich research program adds to our published preclinical and clinical data which has repeatedly shown that
IMM-124E delivers a significant reduction in liver and mucosal inflammation. LPS endotoxins have been widely implicated as a major
driver of inflammation in Colitis, </i></font><i>Inflammatory bowel disease (IBD)<font style="color: black">, NASH as well as numerous
Auto-Immune Diseases&rdquo;.</font></i></p>

<p style="font: 10pt/130% Times New Roman, Times, Serif; margin: 0 13.8pt 0 0; text-align: center">&nbsp;</p>

<p style="font: 10pt/130% Times New Roman, Times, Serif; margin: 0 13.8pt 0 0; text-align: center">- - - END - -</p>



<p style="text-align: center">&nbsp;</p>
<table cellspacing="0" cellpadding="0" border="0" style="width: 100%; border-collapse: collapse; margin-top: 4px;">
<tr>
<td style="vertical-align: top; font: normal 12pt Times New Roman, Times, Serif; margin: 0pt 0; font-weight: normal; text-align: left; text-align: left"><p style="font: 10pt Times New Roman, Times, Serif; font-weight: normal; text-align: left"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #0079C1"><b><u>COMPANY
                                         CONTACT:</u></b></font></p></td>
<td valign="top" style="font: 12pt Times New Roman, Times, Serif; font-weight: normal; margin: 0pt 0; text-align: left;" align="left"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #0079C1">&#160;</font></td>
<td style="vertical-align: top; font: normal 12pt Times New Roman, Times, Serif; margin: 0pt 0; font-weight: normal; text-align: left; text-align: left"><p style="font: 10pt Times New Roman, Times, Serif; font-weight: normal; text-align: left"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #0079C1"><b><u>USA
                                         INVESTOR RELATIONS:</u></b></font></p></td>
<td valign="top" style="font: 12pt Times New Roman, Times, Serif; font-weight: normal; margin: 0pt 0; text-align: left;" align="left"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #0079C1">&#160;</font></td>
<td style="vertical-align: top; font: normal 12pt Times New Roman, Times, Serif; margin: 0pt 0; font-weight: normal; text-align: left; text-align: left"><p style="font: 10pt Times New Roman, Times, Serif; font-weight: normal; text-align: left"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #0079C1"><b><u>AUS
                                         INVESTOR RELATIONS:</u></b></font></p></td></tr>
<tr>
<td style="vertical-align: top; font: 12pt Times New Roman, Times, Serif; margin: 0pt 0; font-weight: normal; text-align: left; text-align: left"><font style="font-size: 8pt">&nbsp;</font></td>
<td style="vertical-align: top; font: 12pt Times New Roman, Times, Serif; margin: 0pt 0; font-weight: normal; text-align: left; text-align: left"><font style="font-size: 8pt">&nbsp;</font></td>
<td style="vertical-align: top; font: 12pt Times New Roman, Times, Serif; margin: 0pt 0; font-weight: normal; text-align: left; text-align: left"><font style="font-size: 8pt">&nbsp;</font></td>
<td style="vertical-align: top; font: 12pt Times New Roman, Times, Serif; margin: 0pt 0; font-weight: normal; text-align: left; text-align: left"><font style="font-size: 8pt">&nbsp;</font></td>
<td style="vertical-align: top; font: 12pt Times New Roman, Times, Serif; margin: 0pt 0; font-weight: normal; text-align: left; text-align: left"><font style="font-size: 8pt">&nbsp;</font></td></tr>
<tr style="background-color: #FFFFFF;">
<td style="width: 31%;" valign="top"><p style="font: 10pt Times New Roman, Times, Serif; font-weight: normal; text-align: left"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Jerry
Kanellos</b></font><br>
<font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief Executive Officer (Interim)</font><br>
<font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Ph: +61 (0)3 9824 5254<br>
jerrykanellos@immuron.com</font></p></td>
<td style="width: 1%;" valign="top"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></td>
<td style="width: 33%;" valign="top"><p style="font: 10pt Times New Roman, Times, Serif; font-weight: normal; text-align: left"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Jon
Cunningham</b></font><br>
<font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">RedChip Companies, Inc.</font><br>
<font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">US Ph: +1 (407)&#160;644 4256, (ext. 107)<br>
jon@redchip.com</font></p></td>
<td style="width: 1%;" valign="top"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></td>
<td style="width: 34%;" valign="top"><p style="font: 10pt Times New Roman, Times, Serif; font-weight: normal; text-align: left"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Peter
Taylor</b></font><br>
<font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">NWR Communications</font><br>
<font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Ph: +61 (0)4 1203 6231<br>
peter@nwrcommunications.com.au</font></p></td></tr></table>
<p style="font: 10pt Times New Roman, Times, Serif; font-weight: bold;"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><u>ABOUT
IMMURON:</u></b></font></p>
<p style="font: 10pt Times New Roman, Times, Serif; font-weight: normal; text-align: justify;"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Immuron
Limited (ASX: IMC, NASDAQ: IMRN), is an Australian microbiome biopharmaceutical company focused on developing and commercializing
orally delivered targeted polyclonal antibodies for the treatment of inflammatory mediated and infectious diseases. Immuron has
a unique and safe technology platform that enables a shorter development therapeutic cycle. The Company currently markets and
sells Travelan<sup>&#x00AE;</sup> for the prevention of Travelers&#x2019; Diarrhea and its lead clinical candidate, IMM-124E,
is in Phase II clinical trials for <b>Non-Alcoholic Steatohepatitis</b> (NASH), <b>Severe Alcoholic Hepatitis</b> (SAH) and Pediatric
<b>Non-Alcoholic Fatty Liver Disease</b> (NAFLD). Immuron&#x2019;s second clinical stage asset, IMM-529, is targeting <b>Clostridium
<i>difficile </i>Infections</b> (CDI). These products together with the Company&#x2019;s other preclinical immunotherapy pipeline
products targeting immune-related diseases currently under development, will meet a large unmet need in the global immunotherapy
market.</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; font-weight: normal; text-align: justify;"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
more information visit: <u>http://www.immuron.com</u></font></p>

<p style="font: 10pt/115% Times New Roman, Times, Serif; margin: 0; background-color: #FEFEFE"><b>About the IMM-124E Study</b></p>

<p style="font: 10pt/115% Times New Roman, Times, Serif; margin: 0; background-color: #FEFEFE"><b>&nbsp;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The IMM-124E study is a Phase II proof of concept
multinational, randomized, double-blind study comparing 2 doses of IMM-124E to placebo for the treatment of NASH in adults with
any stage biopsy-proven NASH. The trial enrolled 133 patients across 25 clinical sites in Australia (6), Israel (2) and the USA
(17). The trial has 12 scheduled visits over a 28-week study duration, with 24 weeks of treatment and four weeks of follow-up and
screened a total of 237 patients. It initially aimed to enroll 120 patients with biopsy-proven NASH, and was fully enrolled at
133 patients, which exceeds the original 120-patient target. The patients were randomized into three arms: placebo, high dose (1200mg),
and low dose (600mg). The established primary endpoints of the study were improvement of liver steatosis, as assessed by magnetic
resonance imaging (MRI) comparing the mean values. The key secondary endpoints are: change in ALT as well as other liver enzymes
and metabolic markers. IMM-124E enrolled adults with all-stage biopsy proven NASH up to 12 months of randomization under an IND
approved by the FDA.</p>

<p style="font: 10pt/115% Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: #FEFEFE; color: #231F20"><b>&nbsp;</b>&nbsp;</p>

<p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif"><img src="img002_v1.jpg" alt="(LOGO)">&nbsp;</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; font-weight: bold;"></p>

<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->
    <p style="font: 10pt Times New Roman, Times, Serif; font-weight: bold">&nbsp;</p>
<p style="font: normal 10pt Times New Roman, Times, Serif; font-weight: normal; text-align: right; border-bottom: Black 1pt solid"><img src="img003_v1.jpg" alt="(IMMURON LIMITED LOGO)">&nbsp;</p>
<p style="font: 10pt Times New Roman, Times, Serif; font-weight: bold"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;<br>
</font><b>About
IMM-124E </b></p>

<p style="font: 10pt/115% Times New Roman, Times, Serif; margin: 0; background-color: #FEFEFE"><b></b></p>

<p style="font: 10pt/115% Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: #FEFEFE">IMM-124E is
an oral, three-times-daily, non-absorbable compound containing poly-clonal anti-LPS immunoglobulins proposed to interact with the
gut LPS and immune system to achieve an immunomodulatory effect reducing LPS-related inflammation and inducing tolerance. Because
of this unique mechanism of action, targeting multiple pathways, IMM-124E has the potential to play a differentiated role in the
management of NASH and may form the cornerstone of NASH combination treatment strategies, both as a single agent and in combination
with other agents.</p>

<p style="font: 10pt/115% Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: #FEFEFE">&nbsp;</p>

<p style="font: 10pt/115% Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: #FEFEFE">In addition
to the adult NASH study, IMM-124E is also being evaluated in two NIH funded Phase II proof-of-concept studies of IMM-124E in children
with Pediatric NAFLD and adults with Severe Alcoholic Hepatitis.</p>

<p style="font: 10pt/115% Times New Roman, Times, Serif; margin: 0; background-color: #FEFEFE"><b>&nbsp;</b></p>

<p style="font: 10pt/115% Times New Roman, Times, Serif; margin: 0; background-color: #FEFEFE"><b>About Non-Alcoholic Steatohepatitis
(NASH)</b></p>

<p style="font: 10pt/115% Times New Roman, Times, Serif; margin: 0; background-color: #FEFEFE">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Nonalcoholic fatty liver disease (NAFLD) is
characterized by a buildup of fat in the liver that is not attributable to excessive alcohol use, NASH is a severe type of NAFLD,
which is characterized by the accumulation of fat in the liver with no other apparent causes. NASH occurs when the accumulation
of liver fat is accompanied by inflammation and cellular damage. The inflammation can lead to fibrosis (scarring) of the liver
and eventually progress to cirrhosis, portal hypertension, liver cancer, and eventual liver failure, requiring the patient to have
a liver transplant.</p>

<p style="font: 10pt/115% Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: #FEFEFE">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">NAFLD is one of the most common causes of liver
disease in the U.S., with the majority of patients having simple fatty liver. It is estimated that between 30-40% of adults in
the U.S. have NAFLD. Although the epidemiology of NAFLD is not fully understood, the condition is associated with certain conditions,
including obesity and obesity related conditions (e.g., type 2 diabetes). Researchers have found NAFLD in 40-80% of people with
type 2 diabetes and in 30-90% of people who are obese. Over 90% of severely obese people undergoing bariatric surgery had NAFLD
in epidemiological studies. NAFLD is not age-specific and has been shown to affect 10% of children ages 2-19, although the risk
of developing NAFLD increases with age.</p>

<p style="font: 10pt/115% Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: #FEFEFE">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">NASH is an emerging health crisis impacting
3% to 5% of the U.S. population and 2% to 4% globally, and is the fastest growing cause of liver cancer and liver transplant in
the U.S. The increasing prevalence of NASH is attributed to the growing obesity epidemic and the disease is often diagnosed in
patients who have diabetes, high cholesterol or high triglycerides. There is currently no approved treatment for NASH. NASH is
projected to reach over $25B annually by 2026 with a compound annual growth rate (CAGR) averaging 45% in the 2018-2026 period.
Research analysts believe that peak sales for IMM-124E could exceed $1.8B in the U.S. alone.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 4pt 0 0; text-align: justify; background-color: white">&nbsp;</p>

<p style="font: 10pt/115% Times New Roman, Times, Serif; margin: 0; background-color: #FEFEFE"><b>About <font style="background-color: white">Lipopolysaccharide
(LPS)</font></b></p>

<p style="font: 10pt/115% Times New Roman, Times, Serif; margin: 0; background-color: #FEFEFE">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><font style="background-color: white">Lipopolysaccharide
(LPS) also known as bacterial endotoxin is the major component of the outer membrane of Gram-negative bacteria which are natural
inhabitants of the mammalian intestinal tract. These enteric bacteria serve as the source for systemic endotoxin exposure. </font>There
is a continuous release of endotoxin (LPS) in the host intestine with no consequence to the individual and if a small amount of
endotoxin leaks into the portal vein, it is cleared by the liver, therefore, never entering the circulatory system. <font style="background-color: white">However,
conditions that interfere with the integrity of the protective intestinal mucosal epithelium, such as our high fat, high sugar,
western diets, chronic alcohol consumption or ischemia, increased LPS absorption into the hepatic portal system occurs. If the
resulting endotoxemia overwhelms the liver&rsquo;s capability to metabolize absorbed LPS, an intense hepatic inflammatory response
ensues<font style="color: #665E58">. </font><font style="color: #222222">When bacterial cells are </font>lysed <font style="color: #222222">by
the </font>immune system<font style="color: #222222">, bacterial fragments containing LPS are released into the circulation, causing
fever, diarrhea, and possible fatal endotoxic shock (also called </font>septic shock<font style="color: #222222">). </font><font style="color: #2E2E2E">Physiological
response to inflammatory mediators can lead to hepatic damage. Elevated serum LPS is associated with increased risk for developing,
Alcoholic Hepatitis, </font>Alzheimer&rsquo;s disease, Auto-immune diseases<font style="color: #2E2E2E">, </font>Cancer<font style="color: #2E2E2E">,
</font>Diabetes<font style="color: #2E2E2E">, </font></font>Heart Disease<font style="color: #2E2E2E; background-color: white">,
</font>Inflammatory Bowel Disease (Crohn&rsquo;s Disease, Ulcerative Colitis<font style="color: #2E2E2E; background-color: white">),
</font>Metabolic Syndrome<font style="color: #2E2E2E; background-color: white">, </font>Non-Alcoholic Fatty Liver Disease and many
others.</p>



<p style="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; font-weight: bold;"></P>

<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->
    <P STYLE="font: 10pt Times New Roman, Times, Serif; font-weight: bold">&nbsp;</P>
<P STYLE="font: normal 10pt Times New Roman, Times, Serif; font-weight: normal; text-align: right; border-bottom: Black 1pt solid"><IMG SRC="img003_v1.jpg" ALT="(IMMURON LIMITED LOGO)">&nbsp;<font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</font></P>

<P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><br>
<b>FORWARD-LOOKING STATEMENTS:</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 4pt 0 0; text-align: justify">This press release may contain &ldquo;forward-looking
statements&rdquo; within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act
of 1934, each as amended. Such statements include, but are not limited to, any statements relating to our growth strategy and
product development programs and any other statements that are not historical facts. Forward-looking statements are based on management&rsquo;s
current expectations and are subject to risks and uncertainties that could negatively affect our business, operating results,
financial condition and stock value. Factors that could cause actual results to differ materially from those currently anticipated
include: risks relating to our growth strategy; our ability to obtain, perform under and maintain financing and strategic agreements
and relationships; risks relating to the results of research and development activities; risks relating to the timing of starting
and completing clinical trials; uncertainties relating to preclinical and clinical testing; our dependence on third-party suppliers;
our ability to attract, integrate and retain key personnel; the early stage of products under development; our need for substantial
additional funds; government regulation; patent and intellectual property matters; competition; as well as other risks described
in our SEC filings. We expressly disclaim any obligation or undertaking to release publicly any updates or revisions to any forward-looking
statements contained herein to reflect any change in our expectations or any changes in events, conditions or circumstances on
which any such statement is based, except as required by law.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 4pt 0 0; text-align: justify">&nbsp;</P>



<P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"></P>



<p style="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"></p>

<!-- Field: Page; Sequence: 3; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<p style="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&nbsp;</font></p></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>img004_v1.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img004_v1.jpg
M_]C_X  02D9)1@ ! @  9 !D  #_[  11'5C:WD  0 $    9   _^X #D%D
M;V)E &3      ?_; (0  0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0(" @(" @(" @(" P,# P,# P,# P$! 0$! 0$" 0$"
M @(! @(# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,#
M P,# P,# P,#_\  $0@ - "( P$1  (1 0,1 ?_$ (T   (#  (# 0
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M$@B(E\0?9Q+NB.7$M[(D+;9K<*M3T)*:RY)Y+]C:Z[+'NQJ.QG')'L:E+,%
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M?D60IJ[Z9CN3'F;Q-5F;A5R=36[67*-%U0J44T.1M[F)L%H:VR;V*NB*:9@
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M>-<*I-_OUWE)MVX4 # U; 4R1$;W\N23:UW5?DUK.;<\QV2L3RF2JAK9K)Q
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7T = '0!T = '0!T = '0!T = '0'_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>4
<FILENAME>img001_v1.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img001_v1.jpg
M_]C_X  02D9)1@ ! @  9 !D  #_[  11'5C:WD  0 $    9   _^X #D%D
M;V)E &3      ?_; (0  0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0(" @(" @(" @(" P,# P,# P,# P$! 0$! 0$" 0$"
M @(! @(# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,#
M P,# P,# P,#_\  $0@ 0@$' P$1  (1 0,1 ?_$ .\   (" @(# 0
M       *" D'"P4& 0,$ @$  @(# 0$!              @'"00%!@,! A
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M2E@_F1"&=Q\*HZB7U/A<HOHAH+J3@754FR(OJ1DMJS2.X&.$3-9%$ISM@1,
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M4480XR5&92A9*5-S..5*@"D<F8@82 43VA]*VZUW"CU%;VTM+K"M#P2)!2T
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M%;1(XI\"W4W\M>M1:)]O3T*Q:!#;?5V-JO2I44UCBAQ#JC_C&+!:5(51-I/
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MWN+%JH0%5E0ZEM ) !4LA*02<!B>)C,N=QI;1;G[I7$IHZ=I3BR 20E *E$
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MUVS.6#96H2Z23AXA"R+U5J@HJ'24YP*43> #OKD-%VB[6W6]F7<:6H80JY,
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M_C_Y4<'I7UC7_P W]ZQX+RGO1Y1_D=$<1W@_BOUGV#^V*L?&&^!7P8NGX/\
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6] G?,_D3W@?-_@U=_P#P7Z;Y.:/_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>5
<FILENAME>img002_v1.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img002_v1.jpg
M_]C_X  02D9)1@ ! @  9 !D  #_[  11'5C:WD  0 $    9   _^X #D%D
M;V)E &3      ?_; (0  0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0(" @(" @(" @(" P,# P,# P,# P$! 0$! 0$" 0$"
M @(! @(# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,#
M P,# P,# P,#_\  $0@ 5 ,Q P$1  (1 0,1 ?_$ /$  0 ! P4! 0
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MV5;Z&OC=%5QG!S3Y001L+2,"UP):YI#FD@@JI3U$-7")Z=P=$<=N[ @X$$'
MM<T@AS2 YI!! ((5ZBT5= 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
M1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
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M<W=.)8P,C;M"JV6FJH8^UD;A>ZIH=*3OB81BR!IVX-B!P?AZTG._>[99N/\
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MMN52\Q]EN1&-WMUP@YV;<5"XL[=2UQ*ODW-_LSN?1R$0I,3<U%#"DRH2)/\
MCTEV&_'\26LB-KGF=LH66MCJ;A8Z9]HO=!*UE?;YG;(><AK9HW;08BX@$CW(
M#@[W+=^?MU_M%^L<>8\OR"LM4T?.QT7NN=NT$M!P.(((+" X$<I&(P7H2Q#,
M\7SW'*_+</NX5]CUFAY<2RAK5X?7&><BS(LEIY+4F#/KY;#C$F,^AM^,^VMM
MU"%I4DN-UU!66VJ=15T;HZIF&+3WQB""-A:X$%K@2' @@D$%7%NN=!=Z)EPM
MLK9J-^.#F[MA(<"#@6N:06N:X!S7 M< 00O+9R(YZ<V>?O*+(.+/E^W-K@N
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M,FE0,=F6E@C73I4N1D%S;0EK+M_R8B/U#IMIZ1=+J' W&:YUSN/-*R)I\43
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M-Y\MS(?)KEC")U?PB5[0228ZC\,GS8SMDWNGN\0VD$DS[]"(>L>K)K>UL<F
MY^2I&/'#&(KSATW./9W9F/N.> X>*4+U%CQTO4" B B B B B B B B B B
MB B B B B B B B B B B B B B B B B B B B B B B B B B B B B B
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M3Z!*7..\E3AK&^J %0E:K5U+,UJ/M-2S-:C/U]2M3$JFQ/! 1 1 1 1 1 1
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M8TJ6Y_IPP4_"B1GY3I)*JRC57A1VW'.DO2>FA#T5TQ/CCU&>Z1S6M_A\VUQ
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M]RE:4Z?0(<SCO)4P:T;@%1UJ4X?4XI3BC[U.*4M7UJ,S$JFQPW+YIIW B B
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MZ=721:Z:F(ESCO)*@&M&X +=$%% 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
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MO6=G([9%C/>U[_$F2%D>OL-S00Q)XJ8 #< N"?VCU49J/UJ,S/ZSU$%'% 1
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M)+1-A-27J1*>27U)61"L)9&[&N</ 51,,+CBYK2>^ MM4^>O\N;+5^M)>/\
M&L0,DAWN=Y2HB*(;FM\@6R;[ZORGWE>]UP_QJ$O,[NE3!K1N \BT&M9]ZUG[
MU*/\9@H[%I$$30O40*.)7S0O47U F)7T$0$0$0$0$0$0$0$0$0$0$0$0$0$0
M$0$0$0$0$0$0$0$0$0$0$0$0$0$0$0$0$0$0$0$0$0$0$0$0$0$0$0$0$0$0
M$0$0$0$0$0$0$0$0$0$0$0$0$0$0$0$0$0$0$0$0$0$0$0$0$0$0$0$0$0$0
M$0$0$0$0$0$0$0$0$0$0$0$0$0$0$0$0$0$0$0$0$0$0$0$0$0$0$0$0$0$0
M$0$0$0$0$0$0$0$0$0$0$0$0$0$0$0$0$0$0$0$0$0$0$0$0$0$0$0$0$0$0
M$0$0$0$0$0$0$0$0$0$0$0$0$0$0$0$0$0$0$0$0$0$0$0$0$0$0$0$0$0$0
..$0$0$0$0$0$0$0$7_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>6
<FILENAME>img003_v1.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img003_v1.jpg
M_]C_X  02D9)1@ ! @  9 !D  #_[  11'5C:WD  0 $    9   _^X #D%D
M;V)E &3      ?_; (0  0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0(" @(" @(" @(" P,# P,# P,# P$! 0$! 0$" 0$"
M @(! @(# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,#
M P,# P,# P,#_\  $0@ +@"T P$1  (1 0,1 ?_$ -$   (#  (# 0
M       )!P@*!08#! L" 0 " P # 0$            '"  %!@(#! D!$
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M118&Q&PT#M'LG9VWTW)W/E!N&"DQ%F6.,L*B,+'^4FEIZP!RBA%" 6PJ6O\
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MAT_'Z0-_8X"V^?\ +_9_);?I6P:-C_X^W?RW/Z)<<OWR-!W\;-2^ _\ "](
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MY<I\F%^[!V=]K.[=6WG.F6V<.M? RSRB5E!\<BJ*^3,OEQ^]V0@'?[V]B/\
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M0X58TKCS;I>W'A/=QF3%^:LDV'(,98,5,8F/AXNJ2D(PAY-M#V9S:6P2I9"
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M.]17?/&SE_;92=+23Q[7AE8=:D.9"5I;FBO'?DE((9M+GB'/4!,'W3!P',
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LO5]'ITQQ]T:3[F]B][R_OA^\>?VGV>6GO7HUZ70R_J_LWH5S=+I>EU*X_]D!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
